Marks LS - Search Results

1

Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia.

Plante MK, Marks LS, Anderson R, Amling C, Rukstalis D, Badlani G, Getlin L, Vang E. Plante MK, et al. Among authors: marks ls. J Urol. 2007 Mar;177(3):1030-5; discussion 1035. doi: 10.1016/j.juro.2006.10.024. J Urol. 2007. PMID: 17296405 Clinical Trial.

2

The fundamental concept, that interindividual differences among prostate glands can explain varying responses to treatment, remains intact. A simple test to pinpoint those differences remains the challenge.

Marks LS. Marks LS. Urology. 2000 Aug 1;56(2):266. doi: 10.1016/s0090-4295(00)00630-0. Urology. 2000. PMID: 10925091 No abstract available.

3

Effects of untreated syphilis in the negro male, 1932 to 1972: a closure comes to the Tuskegee study, 2004.

Baker SM, Brawley OW, Marks LS. Baker SM, et al. Among authors: marks ls. Urology. 2005 Jun;65(6):1259-62. doi: 10.1016/j.urology.2004.10.023. Urology. 2005. PMID: 15922414 No abstract available.

4

5alpha-reductase: history and clinical importance.

Marks LS. Marks LS. Rev Urol. 2004;6 Suppl 9(Suppl 9):S11-21. Rev Urol. 2004. PMID: 16985920 Free PMC article.

5

Ureteral obstruction in the patient with prostatic carcinoma.

Marks LS, Gallo DA. Marks LS, et al. Br J Urol. 1972 Aug;44(4):411-6. doi: 10.1111/j.1464-410x.1972.tb10101.x. Br J Urol. 1972. PMID: 5070145 No abstract available.

6

Arteriography in penetrating renal trauma.

Marks LS, Brosman SA, Lindstrom RR, Fay R. Marks LS, et al. Urology. 1974 Jan;3(1):18-22. doi: 10.1016/s0090-4295(74)80051-8. Urology. 1974. PMID: 4812892 No abstract available.

7

Vesicoureteral reflux from foreign body calculus in the bladder.

Marks LS. Marks LS. J Urol. 1974 Oct;112(4):516-8. doi: 10.1016/s0022-5347(17)59780-3. J Urol. 1974. PMID: 4416865 No abstract available.

8

Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging-visible Disease in Radiorecurrent Prostate Cancer.

Kishan AU, Valle LF, Marks LS. Kishan AU, et al. Among authors: marks ls. Eur Urol. 2024 Jan;85(1):47-48. doi: 10.1016/j.eururo.2023.09.018. Epub 2023 Oct 6. Eur Urol. 2024. PMID: 37805372 No abstract available.

9

Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis.

Hudson J, Cruickshank M, Quinton R, Aucott L, Wu F, Grossmann M, Bhasin S, Snyder PJ, Ellenberg SS, Travison TG, Brock GB, Gianatti EJ, van der Schouw YT, Emmelot-Vonk MH, Giltay EJ, Hackett G, Ramachandran S, Svartberg J, Hildreth KL, Antonic KG, Tenover JL, Tan HM, Ho Chee Kong C, Tan WS, Marks LS, Ross RJ, Schwartz RS, Manson P, Roberts SA, Skovsager Andersen M, Velling Magnussen L, Aceves-Martins M, Gillies K, Hernández R, Oliver N, Dhillo WS, Bhattacharya S, Brazzelli M, Jayasena CN. Hudson J, et al. Among authors: marks ls. Lancet Healthy Longev. 2023 Oct;4(10):e561-e572. doi: 10.1016/S2666-7568(23)00169-1. Lancet Healthy Longev. 2023. PMID: 37804846 Free article.

10

The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement.

Javier-DesLoges J, Dall'Era MA, Brisbane W, Chamie K, Washington SL 3rd, Chandrasekar T, Marks LS, Nguyen H, Daneshvar M, Gin G, Kane CJ, Bagrodia A, Cooperberg MR. Javier-DesLoges J, et al. Among authors: marks ls. Prostate Cancer Prostatic Dis. 2023 Aug 8. doi: 10.1038/s41391-023-00702-1. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37553435 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

207 results

Search Page